Fig. 1From: The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patientsImmunohistochemistry showed the location of CD133 expression in the TU and AN of HCC patients. a A representative low C and low N CD133 immunostaining of HCC using the CD133 antibody (100 x). b A representative high C and low N CD133 immunostaining of HCC using the CD133 antibody (100 X). c A representative low C and high N CD133 immunostaining of HCC using the CD133 antibody (100 X). d A representative high C and high N CD133 immunostaining of HCC using the CD133 antibody (100 X). e A representative low C and low N CD133 immunostaining of AN using the CD133 antibody (100 X). f A representative high C and low N CD133 immunostaining of AN using the CD133 antibody (100 X). g The mean of the cytoplasmic CD133 scores was calculated in the TU and pair-matched AN, and the cytoplasmic CD133 scores were compared in the TU and pair-matched AN. h The mean of the nuclear CD133 scores was calculated in the TU and pair-matched AN, and the nuclear CD133 scores were compared in the TU and pair-matched AN. C: cytoplasm. N: nucleus. TU: tumor. AN: adjacent normal liver tissue. The corresponding isotype control of the CD133 antibody was obtained using normal rabbit IgGBack to article page